These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 1576047

  • 1. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.
    Birgersdotter UM, Wong W, Turgeon J, Roden DM.
    Br J Clin Pharmacol; 1992 Mar; 33(3):275-80. PubMed ID: 1576047
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

  • 5. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J, Fiset C, Giguère R, Gilbert M, Moerike K, Rouleau JR, Kroemer HK, Eichelbaum M, Grech-Bélanger O, Bélanger PM.
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [Abstract] [Full Text] [Related]

  • 6. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
    Haefeli WE, Bargetzi MJ, Follath F, Meyer UA.
    J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
    [Abstract] [Full Text] [Related]

  • 7. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE, Roden DM.
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.
    Circulation; 1983 May; 67(5):1117-23. PubMed ID: 6339110
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. A double-blind randomized study in ambulatory outpatients.
    Salerno DM, Hodges M, Granrud G, Sharkey P.
    Ann Intern Med; 1983 Apr; 98(4):455-60. PubMed ID: 6340575
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A.
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
    Boriani G, Capucci A, Strocchi E, Calliva R, Santarelli A, Biffi M, Magnani B.
    Int J Clin Pharmacol Res; 1993 Sep; 13(4):211-9. PubMed ID: 8150547
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.
    Wang Z, Fermini B, Nattel S.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):184-96. PubMed ID: 7815332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.